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INTRODUCTION 
In course of pathway activation 
fourth component complement is by ac- 
CT into (8800 M,) C4b (197 
M,). It well known C4b forms reversible 
complex the second of comple- 
C2, with essential participation Mg2+ 
[ 1,2]. Furthermore, C4b serves as an acceptor for 
CZ, activated by cleavage by Ci; the complex 
formed, C4b2a,b is independent of Mg2+ and has 
proteolytic activity for C3 and C5. The enzymic site 
resides in the C2a part of the labile complex 12-41, 
expressed only when C2a is bound, not after its 
irreversible dissociation or when generated by CT in 
the absence of C4b. 
facilitates C2 cleavage by acting on the Ci complex, 
an explanation proposed in [5]. Facilitation of C2 
cleavage by interaction of C4b with C2 [6] or by 
action of C4b as product acceptor [8] seem now to 
be excluded. 
2. MATERIALS AND METHODS 
2.1. Buffers 
VBSGG is 2.5 mM barbital buffer (pH 7.4) with 
0.08 M NaCl, 2.5% glucose and 0.1% gelatin. 
VBSGG2+ contains 0.15 mM CaC12 and 0.5 mM 
MgC12, in addition. Ca2+-VBSGG has 0.15 mM 
CaC12, no Mg2’. EDTA-VBSGG contains 0.01 M 
EDTA. VBS lacks glucose and gelatin, and contains 
0.15 MNaCl. 
The involvement of C4b in the process of C2 acti- 
vation remained still unclear. It has been reported 
that C2 cleavage by soluble, free CKiis not affected 
by the presence or absence of C4b [4,5]. However, 
intact Ci, composed of the subcomponents C’i& 
Cir, C lq, cleaves C2 better when C4b is present, in 
the fluid phase as well as when fixed to a surface 
[5,6,81. 
2.2. Cobra inhibitor 
The inhibitor was isolated from 5 g Naja naja 
venom as in 171. 
2.3. Anti-cobra inhibitor 
These experiments were designed to further 
clarify the role of C4b in the enhancement of C2 acti- 
vation by intact CT. Here, we show the abrogation of 
the enhancement by an inhibitor from cobra venom 
which we found to bind C4b [7] and demonstrate that 
C2 cleavage by Ci and its enhancement by C4b are 
Mg2+ independent. Our results indicate that C4b 
Antiserum against the inhibitor was raised in rab- 
bits. The antiserum was passed through a 
column of protein A-Sepharose (Pharmacia), and the 
bound IgG was eluted with 0.4 M NaCl in 0.1 M 
glycine buffer (pH 2.8). Finally the IgG fraction was 
dialyzed against VBS. 
2.4. Complement components 
Abbreviations: CVF, cobra venom factor; EDTA, ethyl- 
enediamine tetraacetic acid 
CT used was prepared from human serum as in 191 
without adding DFP. The preparation contained 6.5 
mg protein/ml estimated by absorption at 280 nm, 
assuming A!& = 10.0. C4 was purified from human 
serum as in [lo]. The preparation contained 25 pg/ml 
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(280 nm). C2 was purified from the 
supematant of human serum precipitated with 20% 
(w/v) NazS04 by chromatography on SP-Sephadex 
and DEAE-cellulose Ill]. 0xyC2 was obtained by 
treatment of C2 with iodine [ 1 I]. Complement com- 
ponents used for haemolytic assay of C2, were pur- 
chased from Cordis Corp. (Miami FL). 
2.5. Immune precipitate (AgAb) 
A solution of human serum albumin (Behring- 
werke, Marburg) (0.25 ml containing 1.25 mg) was 
mixed with 4 ml rabbit anti-human serum albumin 
(Behringwerke) in the presence of 0.01 M EDTA. 
The mixture which contained antibody in excess, 
was left at 4°C overnight. Then the precipitate was 
washed twice with 5 ml EDTA-VBS, twice with 5 
ml VBS containing 1 M NaCl, and twice with VBS 
containing 4 mM NaN3. The precipitate was resus- 
pended in VBS-azide at 2.1 mg/ml, estimated by 
the Folin assay, and was kept frozen in small ali- 
quots at - 70°C. 
2.6. Cellular intermediates 
EACi and EACi4 cells used for studies on cleav- 
age of C2, were prepared with sheep red cells, rabbit 
amboceptor, Cl@ and C4h” [ 111. For the preparation 
of EAC4, used in C2 binding experiments, EACi4 
were shaken for 10 min at room temperature with 
EDTA-VBSGG, centrifuged, washed once with 
VBSGG, twice with VBSGG2+, and resuspended in 
VBSG@ + 
2.7. Estimation of C2 
Binding and cleavage of C2 was assessed by mea- 
suring residual C2 activity in supematants of incuba- 
ted samples. C2 was assayed by immune haemolysis 
using EACfl, Cordis C3hU, CSh” and C6-C9gP. 
Since the cobra inhibitor interfered with the 
haemolytic C2 assay, all samples which did not 
contain it during the incubations (controls), receiv- 
ed it after the reaction. Then anti-cobra inhibi- 
tor-IgG was added to all samples in slight excess. 
3. RESULTS 
3.1. Effect of cobra inhibitor on binding of C2 to 
EA Cq 
EAC4 (2.5 X 10’ cells) were incubated with 0.45 
pg C2 in 200 ~1 total vol. VBSGG2+, for 10 min at 
20°C. After centrifugation, < 10% of the added C2 
196 
was recovered in the supematant. The cell sediment 
was then treated with 200 ~1 EDTA-VBSGG for 10 
min, and the new supematant obtained after centri- 
fugation was supplemented with an equal volume of 
0.0 1 M CaC12 containing 0.0 11 M NaOH to neutralize 
the EDTA without lowering pH. It contained 56% of 
the originally added C2, in haemolytically active 
form. The C2 had been bound to EAC4 and was 
released by EDTA. When the incubation of C2 with 
EAC4 was carried out in the presence of 130 pg/ml 
cobra inhibitor hardly any C2 was bound; >95% 
were recovered in the supernatant, and no measur- 
able C2 activity was released from the cells by 
EDTA-VBSGG (results are means of 2 expt). 
3.2. Eff t f b ec o co ra inhibitor on cleavage of C2 by 
EA CT and EA Cn 
EACi4 (2.5 X 10’ cells) were incubated with 0.45 
pg C2, for 5 min at 3O”C, in 100 ~1 total vol. 
VBSGG2+. Only 6% of the added C2 were recovered 
in the supematant, and no activity could be eluted 
from the cells by EDTA-VBSGG. Thus the loss of 
C2 activity must have been due to nearly complete 
cleavage. In the presence of cobra inhibitor (130 
pg/ml) the cleavage of C2 by EACi4 was reduced to 
only 51%. 
EACi cells cleaved C2 much less efficiently, as 
expected. Incubation of 0.45 fig C2 with 2.5 x IO’ 
EACi in 100 pl(40 min 30°C) led to a loss of 39% C2 
activity. Cobra inhibitor (130 pglml) had no inhibi- 
tory effect; the C2 consumption in its presence was 
37%. These results (means of 2 expt) indicate that 
cobra inhibitor abrogates the enhancing function of 
C4b on C2 activation by the Ci complex. 
3.3. Effect of Mg?+ on cleavage of C2 by Cl and 
C14, and on generation of C3 convertase, Ca 
To further study the effect of C4b and of Mg2+ on 
the activity of Ci against C2 we chose preformed 
immune precipitate (AgAb), as a system which could 
be used in a reproducible manner, from which any 
free Cls could be easily eliminated and which unlike 
red cells would not release unwanted Mg2+ into the 
medium. 
AgAb (525 pg) was incubated with 0.3 pg Cihu in 
730 ~1 Ca2+-VBSGG, for 15 min in an ice water 
bath. Then the precipitate was washed twice with 
Ca2+-VBSGG and resuspended in 250 ~1 
Ca2+-VBSGG. Two 50 ~1 aliquots of AgAbCi in- 
termediate were then treated with 0.3 PLg C4hU for 30 
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Table 1 Table 2 
Cleavage of C2 by AgAbCi and AgAbCa; effect of 
M&J+ 
Generation of C3 cleaving C42 complex on AgAb; effect 
of Mg2+ 
Intermediate Mgz+ 
(mM) 
% C2 cleavage Difference 
(mean f SD) to (1) 
(1) AgAbCi4 4.5 65.3k4.16 
(2) AgAbCTri 0 79.0 + 4.80 p<O.Ol 
(3) AgAbCi 4.5 44.3 k 2.52 p<O.OOl 
(4) AgAbCi 0 44.0 + 3.46 
% 0xYC2 cleavage 
(5) AgAbCi4 4.5 51.5k2.12 p < 0.02 
(6) AgAbCi4 0 56.0 + 4.24 
The intermediates (50 ~1 aliquots) were incubated with 
C2hU (3 expt) or oxYC2 (2 expt), in the presence or absence 
of Mg2+, as indicated. For details see text 
mm at 0°C to obtain AgAbC%i, and 2 others with 
Ca2+-VBSGG for the same time, these remaining in 
the state AgAbCi. Then the aliquots were washed 
twice with Ca2+, resuspended in 50 ~1 
Ca2+-VBSGG, and 50 ~1 of a 1: 100 dilution of C2hU 
in Ca2+-VBSGG were added. One AgAbl4 aliquot 
received 10 ~1 50 mM MgC12 in addition, the other 
Hz0 as control. After 60 min incubation at 30°C the 
mixtures were centrifuged, and residual C2 was 
estimated in the supernatants. 
Table 1 shows that C4b on the intermediate en- 
hances C2 cleavage by CT considerably, and that this 
effect is quite independent of Mg2+. In its absence 
the Cl4 mtermediate cleaves C2 even slightly faster. 
0xyC2 is less efficiently cleaved than C2 (confirming 
[S]), again there is no positive effect of Mg2+ on the 
cleavage. 
To test the effect of Mg2+ on the formation of a C3 
cleaving CD complex AgAb was treated as above 
with CT, C4 and with 0xyC2 in the absence or presence 
of Mg2+. The sediment was washed once with EDTA 
-VBSGG, once with VBSGG, and was then re- 
suspended in 50 ~1 VBSGG. It was incubated with 50 
~1 C3h” (Cordis) for 30 min at 30°C and the residual 
C3 activity in the supematant was taken as a measure 
of C3 convertase activity. There was no C3 cleaving 
activity when Mg2’ was missing, i.e., no C42 complex 
was formed under these conditions (table 2). 
Complex generation % C3 cleavage 
(mean f SD) 
AgAbC14 + ‘=YC2 
50 ~1 + Mg2+ 
50~1- Mg2+ 
200 /Ll + Mg2+ 
200/~- Mg2+ 
10 20.82 
0 +o 
33.5 k 2.5 
0 +_o 
In 3 expt 50 ~1 aliquots of AgAbC%i were incubated with 
“W2 in presence (4.5 mM) or absence of Mg2+. The 
complex was then washed and incubated with C3 to as- 
sess its convertase activity. In two further experiments 
4-times more AgAbCn + 0xYC2 was used. For details 
see text 
4. DISCUSSION 
In [7] cobra inhibitor was shown bind to C4b. We 
now show that it inhibits binding of C2 to C4b. This is 
most likely caused by the affinity of cobra inhibitor 
to C4b, which results in competition with C2 for the 
binding site, or in steric hindrance of C2 attach- 
ment. Since direct cleavage of C2 by EACi is not 
affected, cobra inhibitor is clearly not an enzyme in- 
hibitor nor does it interact effectively with C2. It does, 
however, abolish the enhanced cleavage of C2 by the 
Ci intermediate. In the presence of cobra inhibitor the 
cleavage rate of EAC 14 is reduced to that of EACi. 
Similarly, in [8] the increased cleavage rate of C2 
by EACi4 was reduced to the activity of EACi when 
the C4b on the cells has bound 0xYC2. This indicates 
that both, “yC2 and cobra inhibitor abrogate the 
facilitating effect of C4b. The decision whether C4b 
exerts this effect by interaction with enzyme or sub- 
strate is possible when the effect of Mg2+ is considered. 
Although it is required for binding of C2 to C4b, 
it has no facilitating but even some inhibitory effect 
on C2 cleavage by AgAbCi4, not by AgAbCi. 
These results argue against the possibility that C4b 
facilitates C2 cleavage by substrate modulation; also, 
against a product acceptor function of C4b [8]; 
rather, our results point to an effect of C4b on the 
complex enzyme, ci. 
197 
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However, for the formation of the C3 convertase 
complex, C4b2a,b, Mg*+ is indispensible, in accord- 
ance with earlier findings. Not the slightest activ- 
ity formed in its absence, indicating that activated 
C2 is unable to bind to C4b under these conditions. 
Since the convertase complex contains both C2 
fragments [3,4], C2a remaining attached to C4b with- 
out Mg*+, and since the presence of Mg*+ native 
C2 binds to C4b much more rapidly than cleavage 
by CT proceeds [I], it seems inevitable to conclude 
that the C4bC2a,b complex forms only when C2 is 
bound already before cleavage as proposed in [ 121. 
The other, theoretical possibility that C2 is first 
cleaved, and then both fragments combine with 
C4b, requiring Mg*+ for the attachment but not for 
the persistence of C2a in the complex, is not equally 
conceivable; e.g., not well-compatible with the fact 
that C2a dissociates irreversibly from C4b and, 
hence, cannot be expected to bind to C4b when 
preformed. Lastly, both Ci and C4b are obviously 
in intimate contact (C4b affects Cf activity), and C2 
when approaching CT just cannot escape C4b. The 
sequence: 
Mg2’ CT 
C2 + C4b -+ C4b,C2 - C4b,C2a,b 
is analogous to the formation of the alternative 
pathway convertase, C3bBb and CVF,Bb, which 
also can be generated only when B is bound to C3b 
or CVF before cleavage by any enzyme [ 13,141. 
In conclusion, our results indicate that C4b en- 
hances C2 cleavage by modulation of the complex 
enzyme, Ci, as suggested in [5,6]. Since free Ci 
esterase, C Is, cleaves C2 independent of C4b and at 
about the rate of Cl4 [4,5], confirmed by unpub- 
lished results) it is likely that in the C lq,r,s complex 
some subcomponent (Clr according to [5]) exerts 
an inhibitory effect on Cls which is eliminated by 
interaction with C4b. The C3 cleaving complex 
C4b2a,b probably forms only when C2 is bound 
before cleavage. Cobra inhibitor inhibits C2 acti- 
vation by 2 independent consequences of one effect. 
Its binding to C4b inhibits C4b,C2 formation and 
abrogates the desinhibition of Cl by C4b. 
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